BioWorld Asia

May 8, 2002

GenOway Enters Drug Target Deal, Plans $5.4M Financing

PARIS - GenOway SA signed a nonexclusive agreement with the French pharmaceutical company Servier for the in vivo validation of a number of therapeutic gene targets. (BioWorld International Read More

EU Advisers Support Stem Cell Research, Cautious On Patents

Reprogramming Technique Raises Hopes Of Adult Skin Cell Therapy

Screentec Signals Discovery Ambitions With Name Change

Other News To Note

MMI Raises £1.6M In Placement To Finance Start-Ups, Incubators

Proteome Sciences’ Data Show Sensitivity, Specificity In Test

Personal Chemistry Purchases ESyTech To Extend Platform

Cerep Completes Drug Target Validation Under 1999 BMS Deal

Today's news in brief

BioWorld

BioWorld briefs for Dec. 31, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 30, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...